
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k060429
B. Purpose for Submission:
Clearance of new device
C. Measurand:
Assayed controls for acetaminophen, amikacin, carbamazepine, digoxin, gentamicin,
lidocaine, N-acetyl procainamide, phenobarbital, phenytoin, primidone, procainamide,
quinidine, salicylate, theophylline, tobramycin, valproic acid and vancomycin.
D. Type of Test:
Not applicable.
E. Applicant:
Roche Diagnostics Corporation
F. Proprietary and Established Names:
TDM Control Set
G. Regulatory Information:
Classification Regulation Section Panel
Product Code
Multi-Analyte Controls Class I 21 CFR 862.1660, 75 Clinical
(Assayed And Unassayed) Quality control Chemistry
(JJY) material (assayed and (CH)
unassayed).
H. Intended Use:
1. Intended use(s):
See Indications for Use below.
2. Indication(s) for use:
The TDM Control Set is intended for use as an assayed quality control product on
Roche/Hitachi and COBAS INTEGRA analyzers. Three assayed levels of
acetaminophen, amikacin, carbamazepine, digoxin, gentamicin, lidocaine, N-acetyl
procainamide, phenobarbital, phenytoin, primidone, procainamide, quinidine, salicylate,
theophylline, tobramycin, valproic acid and vancomycin are provided.
1

[Table 1 on page 1]
			Classification	Regulation Section	Panel
					
	Product Code				
Multi-Analyte Controls
(Assayed And Unassayed)
(JJY)			Class I	21 CFR 862.1660,
Quality control
material (assayed and
unassayed).	75 Clinical
Chemistry
(CH)

--- Page 2 ---
3. Special conditions for use statement(s):
For Prescription use only
4. Special instrument requirements:
Roche/Hitachi and COBAS Integra analyzers
I. Device Description:
The TDM Control Set is a human serum based liquid control with seventeen added
therapeutic drugs, preservative and stabilizer. The drugs are acetaminophen, amikacin,
carbamazepine, digoxin, gentamicin, lidocaine, N-acetylprocainamide, phenobarbital,
phenytoin, primidone, procainamide, quinidine, salicylate, theophylline, tobramycin,
valproic acid and vancomycin.
Each TDM Control Set contains 2 bottles of controls (a 5.0 ml fill volume per bottle) at
Levels 1, II and III.
J. Substantial Equivalence Information:
1. Predicate device name(s):
CLINIQA Liquid QC TDM Controls Levels, 1, 2, & 3
2. Predicate 510(k) number(s):
k041898
3. Comparison with the Predicate:
Similarities
Item Device Predicate
Intended Use Assayed quality control material Same
Levels Three Same
Matrix Human serum based liquid Same
Differences
Item Device Predicate
Number of Seventeen Nineteen
Constituents
Constituents acetaminophen, amikacin, acetaminophen, amikacin,
carbamazepine, digoxin, gentamicin, carbamazepine, disopyramide,
lidocaine, N-acetylprocainamide, digoxin, ethosuximide,
phenobarbital, phenytoin, primidone, gentamicin, lidocaine, N-
procainamide, quinidine, salicylate, acetylprocainamide,
theophylline, tobramycin, valproic phenobarbital, phenytoin,
acid and vancomycin. primidone, procainamide,
quinidine, salicylate,
2

[Table 1 on page 2]
Similarities								
	Item			Device			Predicate	
Intended Use			Assayed quality control material			Same		
Levels			Three			Same		
Matrix			Human serum based liquid			Same		

[Table 2 on page 2]
Differences							
	Item			Device		Predicate	
Number of
Constituents			Seventeen			Nineteen	
Constituents			acetaminophen, amikacin,
carbamazepine, digoxin, gentamicin,
lidocaine, N-acetylprocainamide,
phenobarbital, phenytoin, primidone,
procainamide, quinidine, salicylate,
theophylline, tobramycin, valproic
acid and vancomycin.			acetaminophen, amikacin,
carbamazepine, disopyramide,
digoxin, ethosuximide,
gentamicin, lidocaine, N-
acetylprocainamide,
phenobarbital, phenytoin,
primidone, procainamide,
quinidine, salicylate,	

--- Page 3 ---
Differences
Item Device Predicate
Constituents theophylline, tobramycin,
valproic acid and vancomycin.
Target Different assigned values Different assigned values
Range
K. Standard/Guidance Document Referenced (if applicable):
1. ISO 14971:2000, Medical Devices – Application of risk management to medical devices.
2. FDA Guidance: Format for Traditional and Abbreviated 510(k)s.
3. FDA Guidance: Points to Consider Guidance Document on Assayed and Unassayed
Quality Control Material; Draft.
4. FDA Guidance: Points to Consider for Review of Calibration and Quality Control
Labeling for In Vitro Diagnostic Devices.
L. Test Principle:
Not applicable.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Not applicable
b. Linearity/assay reportable range:
Not applicable
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Roche Diagnostics maintains a set of master calibrators for each assay that have values
assigned that are traceable to the various reference standards. The TDM Control Set
products are assayed and traceable to USP standards. Values are assigned using the
Hitachi 917, Module P and COBAS Integra 400/700/800 analyzers. A minimum of two
independent series of analyses are performed on each instrument for each analyte. Each
sample is tested in duplicate. The target value is then calculated as the median of the
determined values. The following tables list lot-specific target values and ranges.
3

[Table 1 on page 3]
Differences							
	Item			Device		Predicate	
Constituents						theophylline, tobramycin,
valproic acid and vancomycin.	
Target
Range			Different assigned values			Different assigned values	

--- Page 4 ---
TDM Control Set Lot 674373 Level 1
Component Method Value Range Unit
15.1 10.6 - 19.6 µg/mL
COBAS INTEGRA
Acetaminophen 100.0 70.0 - 130.0 µmol/L
11.2 7.9 - 14.5 µg/mL
Roche/Hitachi Systems
74.1 51.9 - 96.3 µmol/L
5.33 4.25 - 6.41 µg/mL
COBAS INTEGRA
9.11 7.28 - 10.94 µmol/L
Amikacin
5.14 3.91 - 6.37 µg/mL
ONLINE
8.79 6.69 - 10.89 µmol/L
3.30 2.64 - 3.96 µg/mL
COBAS INTEGRA
14.0 11.3 - 16.7 µmol/L
Carbamazepine 3.30 2.52 - 4.08 µg/mL
CEDIA Roche/Hitachi
14.0 10.7 - 17.3 µmol/L
3.28 2.62 - 3.94 µg/mL
ONLINE
13.9 11.2 - 16.6 µmol/L
0.750 0.450 - 1.050 µg/mL
COBAS INTEGRA
0.960 0.576 - 1.344 µmol/L
Tina-quant 0.740 0.563 - 0.917 µg/mL
Digoxin
Roche/Hitachi 0.947 0.719 - 1.175 µmol/L
1.29 0.90 - 1.68 µg/mL
CEDIA Roche/Hitachi
1.65 1.14 - 2.16 µmol/L
2.12 1.70 - 2.54 µg/mL
COBAS INTEGRA
4.43 3.53 - 5.33 µmol/L
Gentamicin 1.97 1.49 - 2.45 µg/mL
CEDIA Roche/Hitachi
4.12 3.13 - 5.11 µmol/L
2.07 1.65 - 2.49 µg/mL
ONLINE
4.33 3.46 - 5.20 µmol/L
1.46 1.16 - 1.76 µg/mL
Lidocaine COBAS INTEGRA
6.23 4.97 - 7.49 µmol/L
3.96 3.18 - 4.74 µg/mL
COBAS INTEGRA
N-acetylprocainamide 14.3 11.3 - 17.3 µmol/L
3.87 2.94 - 4.80 µg/mL
CEDIA Roche/Hitachi
14.0 10.7 - 17.3 µmol/L
9.88 7.90 - 11.86 µg/mL
COBAS INTEGRA
42.6 34.2 - 51.0 µmol/L
Phenobarbital
9.42 7.53 - 11.31 µg/mL
CEDIA Roche/Hitachi
40.6 32.5 - 48.7 µmol/L
6.37 5.11 - 7.63 µg/mL
COBAS INTEGRA
Phenytoin 25.2 20.1 - 30.3 µmol/L
CEDIA Roche/Hitachi 6.67 5.08 - 8.26 µg/mL
CEDIA Roche Hitachi 26.4 20.1 - 32.7 µmol/L
6.68 5.33 - 8.03 µg/mL
ONLINE
26.5 21.1 - 31.9 µmol/L
2.67 2.13 - 3.21 µg/mL
Primidone COBAS INTEGRA
12.2 9.8 - 14.6 µmol/L
1.76 1.40 - 2.12 µg/mL
COBAS INTEGRA
Procainamide 7.44 5.94 - 8.94 µmol/L
1.66 1.27 - 2.05 µg/mL
CEDIA Roche/Hitachi
7.02 5.34 - 8.70 µmol/L
4

[Table 1 on page 4]
Component	Method	Value	Range	Unit
Acetaminophen	COBAS INTEGRA	15.1
100.0	10.6 - 19.6
70.0 - 130.0	µg/mL
µmol/L
	Roche/Hitachi Systems	11.2
74.1	7.9 - 14.5
51.9 - 96.3	µg/mL
µmol/L
Amikacin	COBAS INTEGRA	5.33
9.11	4.25 - 6.41
7.28 - 10.94	µg/mL
µmol/L
	ONLINE	5.14
8.79	3.91 - 6.37
6.69 - 10.89	µg/mL
µmol/L
Carbamazepine	COBAS INTEGRA	3.30
14.0	2.64 - 3.96
11.3 - 16.7	µg/mL
µmol/L
	CEDIA Roche/Hitachi	3.30
14.0	2.52 - 4.08
10.7 - 17.3	µg/mL
µmol/L
	ONLINE	3.28
13.9	2.62 - 3.94
11.2 - 16.6	µg/mL
µmol/L
Digoxin	COBAS INTEGRA	0.750
0.960	0.450 - 1.050
0.576 - 1.344	µg/mL
µmol/L
	Tina-quant
Roche/Hitachi	0.740
0.947	0.563 - 0.917
0.719 - 1.175	µg/mL
µmol/L
	CEDIA Roche/Hitachi	1.29
1.65	0.90 - 1.68
1.14 - 2.16	µg/mL
µmol/L
Gentamicin	COBAS INTEGRA	2.12
4.43	1.70 - 2.54
3.53 - 5.33	µg/mL
µmol/L
	CEDIA Roche/Hitachi	1.97
4.12	1.49 - 2.45
3.13 - 5.11	µg/mL
µmol/L
	ONLINE	2.07
4.33	1.65 - 2.49
3.46 - 5.20	µg/mL
µmol/L
Lidocaine	COBAS INTEGRA	1.46
6.23	1.16 - 1.76
4.97 - 7.49	µg/mL
µmol/L
N-acetylprocainamide	COBAS INTEGRA	3.96
14.3	3.18 - 4.74
11.3 - 17.3	µg/mL
µmol/L
	CEDIA Roche/Hitachi	3.87
14.0	2.94 - 4.80
10.7 - 17.3	µg/mL
µmol/L
Phenobarbital	COBAS INTEGRA	9.88
42.6	7.90 - 11.86
34.2 - 51.0	µg/mL
µmol/L
	CEDIA Roche/Hitachi	9.42
40.6	7.53 - 11.31
32.5 - 48.7	µg/mL
µmol/L
Phenytoin	COBAS INTEGRA	6.37
25.2	5.11 - 7.63
20.1 - 30.3	µg/mL
µmol/L
	CEDIA Roche/Hitachi
CEDIA Roche Hitachi	6.67
26.4	5.08 - 8.26
20.1 - 32.7	µg/mL
µmol/L
	ONLINE	6.68
26.5	5.33 - 8.03
21.1 - 31.9	µg/mL
µmol/L
Primidone	COBAS INTEGRA	2.67
12.2	2.13 - 3.21
9.8 - 14.6	µg/mL
µmol/L
	COBAS INTEGRA	1.76
7.44	1.40 - 2.12
5.94 - 8.94	µg/mL
µmol/L

--- Page 5 ---
TDM Control Set Lot 674373 Level 1
Component Method Value Range Unit
1.06 0.85 - 1.27 µg/mL
COBAS INTEGRA
3.26 2.60 - 3.92 µmol/L
Quinidine
0.980 0.746 - 1.214 µg/mL
ONLINE
3.02 2.30 - 3.74 µmol/L
Salicylate 43.1 34.4 - 51.8 µg/mL
COBAS INTEGRA
0.312 0.249 - 0.375 µmol/L
5.36 4.28 - 6.44 µg/mL
COBAS INTEGRA
29.7 23.7 - 35.7 µmol/L
4.92 3.75 - 6.09 µg/mL
Theophylline CEDIA Roche/Hitachi
27.3 20.7 - 33.9 µmol/L
5.38 4.30 - 6.46 µg/mL
ONLINE
29.9 23.9 - 35.9 µmol/L
1.55 1.25 - 1.85 µg/mL
COBAS INTEGRA
Tobramycin 3.32 2.66 - 3.98 µmol/L
2.21 1.61 - 2.81 µg/mL
CEDIA Roche/Hitachi
4.73 3.44 - 6.02 µmol/L
36.2 29.0 - 43.4 µg/mL
COBAS INTEGRA
251 200 - 302 µmol/L
Valproic acid
40.8 30.9 - 50.7 µg/mL
CEDIA Roche/Hitachi
283 214 - 352 µmol/L
Vancomycin 6.87 5.49 - 8.25 µg/mL
COBAS INTEGRA
4.74 3.78 - 5.70 µmol/L
TDM Control Set Lot 674373 Level II
Component Method Value Range Unit
34.7 27.8 - 41.6 µg/mL
COBAS INTEGRA
Acetaminophen 230 185 - 275 µmol/L
30.9 23.4 - 38.4 µg/mL
Roche/Hitachi Systems
205 157 - 253 µmol/L
14.2 11.5 - 16.9 µg/mL
COBAS INTEGRA
Amikacin 24.3 19.5 - 29.1 µmol/L
14.5 11.5 - 17.5 µg/mL
ONLINE
24.8 19.7 - 29.9 µmol/L
9.51 7.62 - 11.40 µg/mL
Carbamazepine
COBAS INTEGRA
40.2 32.1 - 48.3 µmol/L
9.30 7.08 - 11.52 µg/mL
CEDIA Roche/Hitachi
39.3 30.0 - 48.6 µmol/L
10.1 8.0 - 12.2 µg/mL
ONLINE
42.7 34.3 - 51.1 µmol/L
1.72 1.39 – 2.05 µg/mL
COBAS INTEGRA
2.20 1.75 - 2.65 µmol/L
Tina-quant 1.80 1.38 - 2.22 µg/mL
Digoxin
Roche/Hitachi 2.30 1.76 - 2.84 µmol/L
2.32 1.75 - 2.89 µg/mL
CEDIA Roche/Hitachi
2.97 2.25 - 3.69 µmol/L
COBAS INTEGRA 5.28 4.23 - 6.33 µg/mL
Gentamicin
5

[Table 1 on page 5]
Component	Method	Value	Range	Unit
Quinidine	COBAS INTEGRA	1.06
3.26	0.85 - 1.27
2.60 - 3.92	µg/mL
µmol/L
	ONLINE	0.980
3.02	0.746 - 1.214
2.30 - 3.74	µg/mL
µmol/L
Salicylate	COBAS INTEGRA	43.1
0.312	34.4 - 51.8
0.249 - 0.375	µg/mL
µmol/L
Theophylline	COBAS INTEGRA	5.36
29.7	4.28 - 6.44
23.7 - 35.7	µg/mL
µmol/L
	CEDIA Roche/Hitachi	4.92
27.3	3.75 - 6.09
20.7 - 33.9	µg/mL
µmol/L
	ONLINE	5.38
29.9	4.30 - 6.46
23.9 - 35.9	µg/mL
µmol/L
Tobramycin	COBAS INTEGRA	1.55
3.32	1.25 - 1.85
2.66 - 3.98	µg/mL
µmol/L
	CEDIA Roche/Hitachi	2.21
4.73	1.61 - 2.81
3.44 - 6.02	µg/mL
µmol/L
Valproic acid	COBAS INTEGRA	36.2
251	29.0 - 43.4
200 - 302	µg/mL
µmol/L
	CEDIA Roche/Hitachi	40.8
283	30.9 - 50.7
214 - 352	µg/mL
µmol/L
Vancomycin	COBAS INTEGRA	6.87
4.74	5.49 - 8.25
3.78 - 5.70	µg/mL
µmol/L

[Table 2 on page 5]
Component	Method	Value	Range	Unit
Acetaminophen	COBAS INTEGRA	34.7
230	27.8 - 41.6
185 - 275	µg/mL
µmol/L
	Roche/Hitachi Systems	30.9
205	23.4 - 38.4
157 - 253	µg/mL
µmol/L
Amikacin	COBAS INTEGRA	14.2
24.3	11.5 - 16.9
19.5 - 29.1	µg/mL
µmol/L
	ONLINE	14.5
24.8	11.5 - 17.5
19.7 - 29.9	µg/mL
µmol/L
Carbamazepine	COBAS INTEGRA	9.51
40.2	7.62 - 11.40
32.1 - 48.3	µg/mL
µmol/L
	CEDIA Roche/Hitachi	9.30
39.3	7.08 - 11.52
30.0 - 48.6	µg/mL
µmol/L
	ONLINE	10.1
42.7	8.0 - 12.2
34.3 - 51.1	µg/mL
µmol/L
Digoxin	COBAS INTEGRA	1.72
2.20	1.39 – 2.05
1.75 - 2.65	µg/mL
µmol/L
	Tina-quant
Roche/Hitachi	1.80
2.30	1.38 - 2.22
1.76 - 2.84	µg/mL
µmol/L
	CEDIA Roche/Hitachi	2.32
2.97	1.75 - 2.89
2.25 - 3.69	µg/mL
µmol/L

--- Page 6 ---
TDM Control Set Lot 674373 Level II
Component Method Value Range Unit
11.0 8.9 - 13.1 µmol/L
5.40 4.11 - 6.69 µg/mL
CEDIA Roche/Hitachi
11.3 8.6 - 14.0 µmol/L
5.43 4.35 - 6.51 µg/mL
ONLINE
11.3 8.9 - 13.7 µmol/L
4.26 3.42 - 5.10 µg/mL
Lidocaine COBAS INTEGRA
18.2 14.6 - 21.8 µmol/L
7.23 5.79 - 8.67 µg/mL
COBAS INTEGRA
N-acetylprocainamide 26.1 21.0 - 31.2 µmol/L
7.19 5.45 - 8.93 µg/mL
CEDIA Roche/Hitachi
26.0 19.7 - 32.3 µmol/L
23.1 18.6 - 27.6 µg/mL
COBAS INTEGRA
99.6 79.8 - 119.4 µmol/L
Phenobarbital
23.3 18.5 - 28.1 µg/mL
CEDIA Roche/Hitachi
100 79 - 121 µmol/L
12.3 9.9 - 14.7 µg/mL
COBAS INTEGRA
48.7 39.1 - 58.3 µmol/L
Phenytoin 13.3 10.0 - 16.6 µg/mL
CEDIA Roche/Hitachi
52.7 40.1 - 65.3 µmol/L
13.0 10.3 - 15.7 µg/mL
ONLINE
51.5 41.3 - 61.7 µmol/L
7.74 6.18 - 9.30 µg/mL
Primidone COBAS INTEGRA
35.4 28.2 - 42.6 µmol/L
7.30 5.83 - 8.77 µg/mL
COBAS INTEGRA
Procainamide 30.9 24.6 - 37.2 µmol/L
7.04 5.36 - 8.72 µg/mL
CEDIA Roche/Hitachi
29.8 22.6 - 37.0 µmol/L
2.98 2.38 - 3.58 µg/mL
Quinidine COBAS INTEGRA
9.18 7.35- 11.01 µmol/L
2.90 2.33 - 3.47 µg/mL
ONLINE
8.93 7.13 -10.73 µmol/L
Salicylate 162 129 - 195 µg/mL
COBAS INTEGRA
1.17 0.93 - 1.41 µmol/L
14.7 11.7 - 17.7 µg/mL
COBAS INTEGRA
81.6 65.4 - 97.8 µmol/L
14.1 10.8 - 17.4 µg/mL
Theophylline CEDIA Roche/Hitachi
78.3 59.4 - 97.2 µmol/L
14.6 11.6 - 17.6 µg/mL
ONLINE
81.0 64.8 - 97.2 µmol/L
3.62 2.90 - 4.34 µg/mL
COBAS INTEGRA
Tobramycin 7.75 6.19 - 9.31 µmol/L
4.86 3.54 - 6.18 µg/mL
CEDIA Roche/Hitachi
10.4 7.7 - 13.1 µmol/L
76.9 61.6 - 92.2 µg/mL
COBAS INTEGRA
533 425 - 641 µmol/L
Valproic acid
85.2 64.8- 105.6 µg/mL
CEDIA Roche/Hitachi
590 449 - 731 µmol/L
COBAS INTEGRA 22.3 17.8 - 26.8 µg/mL
Vancomycin
6

[Table 1 on page 6]
Component	Method	Value	Range	Unit
		11.0	8.9 - 13.1	µmol/L
	CEDIA Roche/Hitachi	5.40
11.3	4.11 - 6.69
8.6 - 14.0	µg/mL
µmol/L
	ONLINE	5.43
11.3	4.35 - 6.51
8.9 - 13.7	µg/mL
µmol/L
Lidocaine	COBAS INTEGRA	4.26
18.2	3.42 - 5.10
14.6 - 21.8	µg/mL
µmol/L
N-acetylprocainamide	COBAS INTEGRA	7.23
26.1	5.79 - 8.67
21.0 - 31.2	µg/mL
µmol/L
	CEDIA Roche/Hitachi	7.19
26.0	5.45 - 8.93
19.7 - 32.3	µg/mL
µmol/L
Phenobarbital	COBAS INTEGRA	23.1
99.6	18.6 - 27.6
79.8 - 119.4	µg/mL
µmol/L
	CEDIA Roche/Hitachi	23.3
100	18.5 - 28.1
79 - 121	µg/mL
µmol/L
Phenytoin	COBAS INTEGRA	12.3
48.7	9.9 - 14.7
39.1 - 58.3	µg/mL
µmol/L
	CEDIA Roche/Hitachi	13.3
52.7	10.0 - 16.6
40.1 - 65.3	µg/mL
µmol/L
	ONLINE	13.0
51.5	10.3 - 15.7
41.3 - 61.7	µg/mL
µmol/L
Primidone	COBAS INTEGRA	7.74
35.4	6.18 - 9.30
28.2 - 42.6	µg/mL
µmol/L
Procainamide	COBAS INTEGRA	7.30
30.9	5.83 - 8.77
24.6 - 37.2	µg/mL
µmol/L
	CEDIA Roche/Hitachi	7.04
29.8	5.36 - 8.72
22.6 - 37.0	µg/mL
µmol/L
Quinidine	COBAS INTEGRA	2.98
9.18	2.38 - 3.58
7.35- 11.01	µg/mL
µmol/L
	ONLINE	2.90
8.93	2.33 - 3.47
7.13 -10.73	µg/mL
µmol/L
Salicylate	COBAS INTEGRA	162
1.17	129 - 195
0.93 - 1.41	µg/mL
µmol/L
Theophylline	COBAS INTEGRA	14.7
81.6	11.7 - 17.7
65.4 - 97.8	µg/mL
µmol/L
	CEDIA Roche/Hitachi	14.1
78.3	10.8 - 17.4
59.4 - 97.2	µg/mL
µmol/L
	ONLINE	14.6
81.0	11.6 - 17.6
64.8 - 97.2	µg/mL
µmol/L
Tobramycin	COBAS INTEGRA	3.62
7.75	2.90 - 4.34
6.19 - 9.31	µg/mL
µmol/L
	CEDIA Roche/Hitachi	4.86
10.4	3.54 - 6.18
7.7 - 13.1	µg/mL
µmol/L
Valproic acid	COBAS INTEGRA	76.9
533	61.6 - 92.2
425 - 641	µg/mL
µmol/L
	CEDIA Roche/Hitachi	85.2
590	64.8- 105.6
449 - 731	µg/mL
µmol/L
Vancomycin	COBAS INTEGRA			

--- Page 7 ---
TDM Control Set Lot 674373 Level II
Component Method Value Range Unit
15.4 12.4 - 18.4 µmol/L
TDM Control Set Lot 674373 Level III
Component Method Value Range Unit
109 88 - 130 µg/mL
COBAS INTEGRA
Acetaminophen 722 578 - 866 µmol/L
105 81 - 129 µg/mL
Roche/Hitachi Systems
695 527 - 863 µmol/L
26.4 21.0 - 31.8 µg/mL
COBAS INTEGRA
45.1 36.1 - 54.1 µmol/L
Amikacin
29.8 23.8 - 35.8 µg/mL
ONLINE
51.0 40.8 - 61.2 µmol/L
15.6 12.6 - 18.6 µg/mL
COBAS INTEGRA
66.0 52.8 - 79.2 µmol/L
Carbamazepine 14.8 11.2 - 18.4 µg/mL
CEDIA Roche/Hitachi
62.6 47.6 - 77.6 µmol/L
15.6 12.6 - 18.6 µg/mL
ONLINE
66.0 52.8 - 79.2 µmol/L
3.48 2.10 - 4.86 µg/mL
COBAS INTEGRA
4.45 2.68 - 6.22 µmol/L
Tina-quant 3.54 2.70 - 4.38 µg/mL
Digoxin
Roche/Hitachi 4.53 3.45 - 5.61 µmol/L
3.95 2.99 - 4.91 µg/mL
CEDIA Roche/Hitachi
5.06 3.86 - 6.26 µmol/L
8.07 6.45 - 9.69 µg/mL
COBAS INTEGRA
Gentamicin 16.9 13.6 - 20.2 µmol/L
8.31 6.06 - 10.56 µg/mL
CEDIA Roche/Hitachi
17.4 12.6 - 22.2 µmol/L
8.31 6.66 - 9.96 µg/mL
ONLINE
17.4 13.8 - 21.0 µmol/L
6.46 5.17 - 7.75 µg/mL
Lidocaine COBAS INTEGRA
27.6 22.2 - 33.0 µmol/L
12.1 9.7 - 14.5 µg/mL
COBAS INTEGRA
N-acetylprocainamide 43.7 35.0 - 52.4 µmol/L
12.7 9.7 - 15.7 µg/mL
CEDIA Roche/Hitachi
45.8 34.7 - 56.9 µmol/L
42.8 34.1 - 51.5 µg/mL
COBAS INTEGRA
184 148 - 220 µmol/L
Phenobarbital
45.3 36.3 - 54.3 µg/mL
CEDIA Roche/Hitachi
195 156 - 234 µmol/L
22.1 17.6 - 26.6 µg/mL
COBAS INTEGRA
87.5 70.1 - 104.9 µmol/L
Phenytoin 24.0 18.3 - 29.7 µg/mL
CEDIA Roche/Hitachi
95.0 72.2 - 117.8 µmol/L
22.8 18.3 - 27.3 µg/mL
ONLINE
90.3 72.3 - 108.3 µmol/L
16.1 12.8 - 19.4 µg/mL
Primidone COBAS INTEGRA
73.7 59.0 - 88.4 µmol/L
7

[Table 1 on page 7]
Component	Method	Value	Range	Unit
		15.4	12.4 - 18.4	µmol/L

[Table 2 on page 7]
Component	Method	Value	Range	Unit
Acetaminophen	COBAS INTEGRA	109
722	88 - 130
578 - 866	µg/mL
µmol/L
	Roche/Hitachi Systems	105
695	81 - 129
527 - 863	µg/mL
µmol/L
Amikacin	COBAS INTEGRA	26.4
45.1	21.0 - 31.8
36.1 - 54.1	µg/mL
µmol/L
	ONLINE	29.8
51.0	23.8 - 35.8
40.8 - 61.2	µg/mL
µmol/L
Carbamazepine	COBAS INTEGRA	15.6
66.0	12.6 - 18.6
52.8 - 79.2	µg/mL
µmol/L
	CEDIA Roche/Hitachi	14.8
62.6	11.2 - 18.4
47.6 - 77.6	µg/mL
µmol/L
	ONLINE	15.6
66.0	12.6 - 18.6
52.8 - 79.2	µg/mL
µmol/L
Digoxin	COBAS INTEGRA	3.48
4.45	2.10 - 4.86
2.68 - 6.22	µg/mL
µmol/L
	Tina-quant
Roche/Hitachi	3.54
4.53	2.70 - 4.38
3.45 - 5.61	µg/mL
µmol/L
	CEDIA Roche/Hitachi	3.95
5.06	2.99 - 4.91
3.86 - 6.26	µg/mL
µmol/L
Gentamicin	COBAS INTEGRA	8.07
16.9	6.45 - 9.69
13.6 - 20.2	µg/mL
µmol/L
	CEDIA Roche/Hitachi	8.31
17.4	6.06 - 10.56
12.6 - 22.2	µg/mL
µmol/L
	ONLINE	8.31
17.4	6.66 - 9.96
13.8 - 21.0	µg/mL
µmol/L
Lidocaine	COBAS INTEGRA	6.46
27.6	5.17 - 7.75
22.2 - 33.0	µg/mL
µmol/L
N-acetylprocainamide	COBAS INTEGRA	12.1
43.7	9.7 - 14.5
35.0 - 52.4	µg/mL
µmol/L
	CEDIA Roche/Hitachi	12.7
45.8	9.7 - 15.7
34.7 - 56.9	µg/mL
µmol/L
Phenobarbital	COBAS INTEGRA	42.8
184	34.1 - 51.5
148 - 220	µg/mL
µmol/L
	CEDIA Roche/Hitachi	45.3
195	36.3 - 54.3
156 - 234	µg/mL
µmol/L
Phenytoin	COBAS INTEGRA	22.1
87.5	17.6 - 26.6
70.1 - 104.9	µg/mL
µmol/L
	CEDIA Roche/Hitachi	24.0
95.0	18.3 - 29.7
72.2 - 117.8	µg/mL
µmol/L
	ONLINE	22.8
90.3	18.3 - 27.3
72.3 - 108.3	µg/mL
µmol/L
Primidone	COBAS INTEGRA	16.1
73.7	12.8 - 19.4
59.0 - 88.4	µg/mL
µmol/L

--- Page 8 ---
TDM Control Set Lot 674373 Level III
Component Method Value Range Unit
11.5 9.1 - 13.9 µg/mL
COBAS INTEGRA
Procainamide 48.6 39.0 - 58.2 µmol/L
10.6 8.2 - 13.0 µg/mL
CEDIA Roche/Hitachi
44.8 34.0 - 55.6 µmol/L
4.78 3.82 - 5.74 µg/mL
COBAS INTEGRA
14.7 11.7 - 17.7 µmol/L
Quinidine
4.59 3.66 - 5.52 µg/mL
ONLINE
14.1 11.4 - 16.8 µmol/L
Salicylate 442 355 - 529 µg/mL
COBAS INTEGRA
3.20 2.57 - 3.83 µmol/L
29.5 23.5 - 35.5 µg/mL
COBAS INTEGRA
164 131 - 197 µmol/L
28.5 21.6 - 35.4 µg/mL
Theophylline CEDIA Roche/Hitachi
158 119 - 197 µmol/L
29.6 23.6 - 35.6 µg/mL
ONLINE
164 131 - 197 µmol/L
7.68 6.15 - 9.21 µg/mL
COBAS INTEGRA
Tobramycin 16.4 13.1 - 19.7 µmol/L
9.82 7.18 - 12.46 µg/mL
CEDIA Roche/Hitachi
21.0 15.3 - 26.7 µmol/L
COBAS INTEGRA 122 98 - 146 µg/mL
Valproic acid COBAS INTEGRA 845 677 - 1.013 µmol/L
132 96 - 168 µg/mL
CEDIA Roche/Hitachi
915 669 - 1.161 µmol/L
Vancomycin 35.2 28.3 - 42.1 µg/mL
COBAS INTEGRA
24.3 19.5 - 29.1 µmol/L
The sponsor performed the following studies to verify the stability claims for the
TDM Control Set.
Stability Unopened Opened
TDM Store at 2 - 8ºC until 12 months at 2–8ºC.
Control Set expiration date
Unopened: The TDM Control Set products were stored at 45ºC for 10 days, 37ºC
every other day for 20 days, 32ºC every third day for 30 days for a total of ten bottles
per level. Each vial was assayed in triplicate using the Integra 400 and compared to
the reference that was initially stored at-70ºC. The product met the sponsor’s
acceptance criterion (95-105% of the reference). The sponsor is continuing real-time
stability studies using the COBAS Integra TDM Assays on the Integra 400 or 700
analyzers.
Opened: The TDM Control Set products were sampled frequently over 120 days.
Vials were tested every 30 days and compared to newly opened vials of TDM Control
8

[Table 1 on page 8]
Component	Method	Value	Range	Unit
Procainamide	COBAS INTEGRA	11.5
48.6	9.1 - 13.9
39.0 - 58.2	µg/mL
µmol/L
	CEDIA Roche/Hitachi	10.6
44.8	8.2 - 13.0
34.0 - 55.6	µg/mL
µmol/L
Quinidine	COBAS INTEGRA	4.78
14.7	3.82 - 5.74
11.7 - 17.7	µg/mL
µmol/L
	ONLINE	4.59
14.1	3.66 - 5.52
11.4 - 16.8	µg/mL
µmol/L
Salicylate	COBAS INTEGRA	442
3.20	355 - 529
2.57 - 3.83	µg/mL
µmol/L
Theophylline	COBAS INTEGRA	29.5
164	23.5 - 35.5
131 - 197	µg/mL
µmol/L
	CEDIA Roche/Hitachi	28.5
158	21.6 - 35.4
119 - 197	µg/mL
µmol/L
	ONLINE	29.6
164	23.6 - 35.6
131 - 197	µg/mL
µmol/L
Tobramycin	COBAS INTEGRA	7.68
16.4	6.15 - 9.21
13.1 - 19.7	µg/mL
µmol/L
	CEDIA Roche/Hitachi	9.82
21.0	7.18 - 12.46
15.3 - 26.7	µg/mL
µmol/L
Valproic acid	COBAS INTEGRA
COBAS INTEGRA	122
845	98 - 146
677 - 1.013	µg/mL
µmol/L
	CEDIA Roche/Hitachi	132
915	96 - 168
669 - 1.161	µg/mL
µmol/L
Vancomycin	COBAS INTEGRA	35.2
24.3	28.3 - 42.1
19.5 - 29.1	µg/mL
µmol/L

[Table 2 on page 8]
Stability	Unopened	Opened
TDM
Control Set	Store at 2 - 8ºC until
expiration date	12 months at 2–8ºC.

--- Page 9 ---
Set products. The product met the sponsor’s acceptance criterion (recovery at ±5% of
the newly opened vials.) The sponsor is continuing opened vial real-time stability
studies.
d. Detection limit:
Not applicable
e. Analytical specificity:
Not applicable
f. Assay cut-off:
Not applicable
2. Comparison studies:
a. Method comparison with predicate device:
Not applicable
b. Matrix comparison:
Not applicable
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable
4. Clinical cut-off:
Not applicable
5. Expected values/Reference range:
Not applicable
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
9